Ivabradine Pharmathen

Ivabradine, the active ingredient in Ivabradine Pharmathen, is a If channel inhibitor presented as an oral tablet for oral use. It is used to lower heart rate in patients with chronic stable angina and heart failure with reduced ejection fraction. GNH USA supplies Ivabradine Pharmathen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current, providing heart‑rate reduction for specific cardiovascular conditions. Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. Heart failure with reduced ejection fraction: lowers resting heart rate, improving symptoms and decreasing hospitalisations. Patients with a resting heart rate ≥70 bpm despite optimal therapy: helps achieve target heart‑rate control when added to standard treatment.

Ivabradine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Visual disturbances (phosphenes or luminous phenomena) - Bradycardia (heart rate below 50 bpm) - Headache - Dizziness or light‑headedness - Fatigue or weakness - Nausea

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention - Atrial fibrillation or other supraventricular arrhythmias - Severe hypotension - Persistent visual impairment - Hepatic dysfunction or elevated liver enzymes

Before initiating therapy, clinicians should evaluate cardiac status and concomitant medications. - Cardiac monitoring: assess resting heart rate and ECG prior to start. - Contraindicated in severe hypotension: avoid if systolic BP <90 mmHg. - Caution in sick‑sinus syndrome: risk of excessive bradycardia. - Avoid strong CYP3A4 inhibitors: may increase plasma levels. - Use with caution in hepatic impairment: dose adjustment may be required. - Store at below 25°C: keep in the original pack, protect from moisture.

Ivabradine interacts with several drug classes that influence heart rate or its metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, itraconazole) - Other bradycardic agents (beta‑blockers, diltiazem, verapamil) - Concomitant use with other If channel blockers

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampicin, carbamazepine, phenytoin) - Digoxin (pharmacodynamic interaction affecting cardiac rhythm) - Diuretics that may cause electrolyte shifts influencing heart rate